Schinkel AH - Search Results

1

Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.

van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ. van Loevezijn A, et al. Among authors: schinkel ah. Bioorg Med Chem Lett. 2001 Jan 8;11(1):29-32. doi: 10.1016/s0960-894x(00)00588-6. Bioorg Med Chem Lett. 2001. PMID: 11140726

2

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. Allen JD, et al. Among authors: schinkel ah. Cancer Res. 1999 Sep 1;59(17):4237-41. Cancer Res. 1999. PMID: 10485464

3

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. Jonker JW, et al. Among authors: schinkel ah. J Natl Cancer Inst. 2000 Oct 18;92(20):1651-6. doi: 10.1093/jnci/92.20.1651. J Natl Cancer Inst. 2000. PMID: 11036110

4

Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.

Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. Allen JD, et al. Among authors: schinkel ah. Cancer Res. 2000 Oct 15;60(20):5761-6. Cancer Res. 2000. PMID: 11059771

5

Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.

Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH. Schellens JH, et al. Among authors: schinkel ah. Ann N Y Acad Sci. 2000;922:188-94. doi: 10.1111/j.1749-6632.2000.tb07037.x. Ann N Y Acad Sci. 2000. PMID: 11193894

6

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.

Allen JD, Jackson SC, Schinkel AH. Allen JD, et al. Among authors: schinkel ah. Cancer Res. 2002 Apr 15;62(8):2294-9. Cancer Res. 2002. PMID: 11956086

7

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH. Allen JD, et al. Among authors: schinkel ah. Mol Cancer Ther. 2002 Apr;1(6):417-25. Mol Cancer Ther. 2002. PMID: 12477054

8

Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2).

Allen JD, Schinkel AH. Allen JD, et al. Among authors: schinkel ah. Mol Cancer Ther. 2002 Apr;1(6):427-34. Mol Cancer Ther. 2002. PMID: 12477055 Review. No abstract available.

9

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH. Huisman MT, et al. Among authors: schinkel ah. J Pharmacol Exp Ther. 2003 Feb;304(2):596-602. doi: 10.1124/jpet.102.044388. J Pharmacol Exp Ther. 2003. PMID: 12538811

10

Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.

Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. Allen JD, et al. Among authors: schinkel ah. Cancer Res. 2003 Mar 15;63(6):1339-44. Cancer Res. 2003. PMID: 12649196

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters